RHYTHM PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Increase (Decrease) in Accounts Receivable of $14.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $6.22M, a 20.63% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $8.11M.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$6.17M.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $6.60M, a 286.42% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $7.57M, a 107.68% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $3.65M, a 57.83% decline from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $8.64M, a 66.24% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $5.20M, a 315.92% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $14.33M 10-Q · filed 2026-08-04 | $8.15M derived: sum of 3 quarters · filed 2026-08-04 | $14.75M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $8.11M 10-Q · filed 2026-05-05 | $1.94M derived: sum of 2 quarters · filed 2026-05-05 | $8.54M derived: sum of 3 quarters · filed 2026-05-05 | $16.37M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $425.00K derived: sum of 2 quarters · filed 2026-02-26 | $8.26M derived: sum of 3 quarters · filed 2026-08-04 | $7.57M 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $14.43M derived: sum of 2 quarters · filed 2026-08-04 | $13.74M 10-Q · filed 2025-11-04 | $12.95M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $7.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $7.14M 10-Q · filed 2026-08-04 | $6.35M derived: sum of 3 quarters · filed 2026-08-04 | $8.06M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$687.00K 10-Q · filed 2026-05-05 | -$1.48M derived: sum of 2 quarters · filed 2026-05-05 | $227.00K derived: sum of 3 quarters · filed 2026-05-05 | $3.13M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$794.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $914.00K derived: sum of 2 quarters · filed 2026-02-26 | $3.82M derived: sum of 3 quarters · filed 2026-02-26 | $3.65M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.61M derived: sum of 2 quarters · filed 2025-11-04 | $4.44M 10-Q · filed 2025-11-04 | $4.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.73M 10-Q · filed 2025-08-05 | $3.06M derived: sum of 3 quarters · filed 2026-02-26 | $3.77M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$172.00K 10-Q · filed 2025-05-07 | $154.00K derived: sum of 2 quarters · filed 2026-02-26 | $864.00K derived: sum of 3 quarters · filed 2026-02-26 | $6.58M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $326.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.04M derived: sum of 2 quarters · filed 2026-02-26 | $6.75M derived: sum of 3 quarters · filed 2026-02-26 | $8.64M 10-K · filed 2026-02-26 |
| 2023-09-30 | $710.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $6.42M derived: sum of 2 quarters · filed 2024-11-06 | $8.32M 10-Q · filed 2024-11-06 | $11.21M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $5.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $7.61M 10-Q · filed 2024-08-06 | $10.50M derived: sum of 3 quarters · filed 2025-02-28 | $11.10M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.89M 10-Q · filed 2024-05-07 | $4.79M derived: sum of 2 quarters · filed 2025-02-28 | $5.39M derived: sum of 3 quarters · filed 2025-02-28 | |
| 2022-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $3.49M derived: sum of 2 quarters · filed 2025-02-28 | $5.20M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $598.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.30M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $1.71M 10-Q · filed 2023-08-01 | |||
| 2021-12-31 | $1.25M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |